New vaccine support (NVS) for PENTA

GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. The pentavalent vaccine, administered in a three-dose schedule, offers protection against five diseases: diphtheria-tetanus-pertussis (DTP), heptatitis B and Haemophilius influenzae type b. Until 2013, GAVI has helped to introduce the pentavalent in 70 of the 73 GAVI-eligible countries, with the aim of reaching all 73 by the end of 2014. GAVI support for pentavalent vaccine is in line with WHO recommendations, for routine infant immunisation and primarily targeting children under one year of age.

Project ID
47122-1820-LBR-04C-X
Activity status
2 - Implementation
Aid type
B02 - Core contributions to multilateral institutions
% to Liberia
100.00

Organisations

Funding
The Global Alliance for Vaccination and Immunisation
Extending
World Health Organisation - core voluntary contributions account (for technical assitance)
Accountable
Federal States & Local Governments
Implementing
Federal States & Local Governments
Extending
United Nations Childrens Fund

Disbursements by fiscal year, quarter

Fiscal year Fiscal quarter Value (USD) Liberia Value (USD)
2018 Q2 -1,376.00 -1,376.00
2017 Q4 168,872.00 168,872.00
2017 Q2 158,800.00 158,800.00

Commitments by fiscal year, quarter

Fiscal year Fiscal quarter Value (USD) Liberia Value (USD)
2018 Q2 332,000.00 332,000.00
2017 Q2 368,500.00 368,500.00

MTEF projections by fiscal year

Fiscal year Value (USD) Liberia Value (USD)
2020 175,750.00 175,750.00
2019 344,500.00 344,500.00
2018 353,000.00 353,000.00
2017 184,250.00 184,250.00

CRS code %
Infectious disease control (12250) 100.0